Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory diseaseKačar, Mark (Avtor) Fitton, John (Avtor) Gough, Andrew K (Avtor) Buch, Maya H (Avtor) McGonagle, Dennis (Avtor) Savic, Sinisa (Avtor) adult onset Still's disease -- drug therapyankylosing spondylitisarthritisantirheumatic agentsundifferentiated systemic autoinflammatory diseasedisease-modifying antirheumatic drugsThis clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still's disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease nonresponsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.BMJ Publishing20202021-04-08 14:38:02Neznano13872UDK: 616-002ISSN pri članku: 2056-5933DOI: 10.1136/ rmdopen-2020-001246COBISS_ID: 58397187sl© Author(s) (or their employer(s)) 2020.